Haemonetics Corporation (HAE) earnings
HAE earnings moved a median of -2.43% by the close. Quarterly and annual HAE reports and results, each read against the price at its own news timestamp. Back to the HAE overview →
20 measured HAE earnings events.
Where these HAE earnings landedvs 20 measured HAE earnings reactions
| Middle 50% of HAE earnings reactions | -4.16% to +1.83% |
|---|---|
| Median reaction (to close) | -2.43% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 HAE earnings events with a measured close landed between -4.16% and +1.83%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q HAEMONETICS CORP For: Jun 27 | SEC filing · Form 10-Q | -2.83% | -0.87% | |
| Form 10-K HAEMONETICS CORP For: Mar 28 | SEC filing · Form 10-K | -0.92% | +5.17% | |
| Form 10-Q HAEMONETICS CORP For: Dec 27 | SEC filing · Form 10-Q | -1.15% | -1.41% | |
| Form 10-Q HAEMONETICS CORP For: Sep 27 | SEC filing · Form 10-Q | +6.64% | +14.62% | |
| Form 10-Q HAEMONETICS CORP For: Jun 28 | SEC filing · Form 10-Q | -4.90% | -21.16% | |
| Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website | Press release | -4.90% | -21.16% | |
| Form 10-K HAEMONETICS CORP For: Mar 29 | SEC filing · Form 10-K | +0.00% | -2.09% | |
| Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website | Press release | -0.40% | +1.78% | |
| Form 10-Q HAEMONETICS CORP For: Dec 28 | SEC filing · Form 10-Q | -1.58% | -3.09% | |
| Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website | Press release | -1.58% | -3.09% | |
| Form 10-Q HAEMONETICS CORP For: Sep 28 | SEC filing · Form 10-Q | +0.26% | +2.16% | |
| Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website | Press release | +0.26% | +2.16% | |
| Form 10-Q HAEMONETICS CORP For: Jun 29 | SEC filing · Form 10-Q | -8.50% | -10.43% | |
| Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website | Press release | -8.50% | -10.43% | |
| Form 10-K HAEMONETICS CORP For: Mar 30 | SEC filing · Form 10-K | -0.75% | +0.20% | |
| Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website | Press release | -2.30% | +1.98% | |
| Form 10-Q HAEMONETICS CORP For: Dec 30 | SEC filing · Form 10-Q | -0.86% | -4.16% | |
| Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website | Press release | -0.86% | -4.16% | |
| Form 10-Q HAEMONETICS CORP For: Sep 30 | SEC filing · Form 10-Q | +1.11% | -2.78% | |
| Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website | Press release | +1.11% | -2.78% |
Keep exploring
More HAE: analyst actions → · SEC filings → · HAE overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| iBio, Inc. (IBIO) | 263 | -0.38% | 43% |
| NOVUS THERAPEUTICS (NVUS) | 263 | -0.14% | 40% |
| Avanos Medical, Inc. (AVNS) | 259 | 0.00% | 45% |
| Enanta Pharmaceuticals, Inc. (ENTA) | 257 | +0.06% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.